FeesSafety
Pluang+

NextCure advances merger with Avere Therapeutics backed by $820M financing, stockholder vote set for Dec 9, 2026

Company Fundamentals
10 Nov 2026, 23:05 WIB
GlobeNewsWire
View Source
Bullish
NextCure advances merger with Avere Therapeutics backed by $820M financing, stockholder vote set for Dec 9, 2026

NextCure announced progress on its merger with Avere Therapeutics, supported by $820 million in committed financing to fund Avere's lead drug development and future operations. The SEC declared the merger registration effective, and a stockholder vote is scheduled for December 9, 2026. NextCure is restructuring and monetizing legacy assets while preparing to operate as Avere post-merger, trading under ticker AVRX. The merger aims to create long-term value for shareholders, pending regulatory and stockholder approvals.

NextCure's business update and Q3 2026 results provide context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 11, 2026 04:02 WIB: of 150 priced health-sector US stocks, 52 rose and 97 fell. Notable movers include ACAD at USD 18.36 with a +11.24% change, IONS at USD 28.10 down -9.35%, and CRSP at USD 45.67 down -8.73%.

More News

Cannabis Strategic Ventures completes control change with Scopien Technologies, rebrands and plans SEC listing.

Cannabis Strategic Ventures completes control change with Scopien Technologies, rebrands and plans SEC listing.

Cannabis Strategic Ventures has finalized its change of control with Scopien Technologies, an AI platform company, which now holds voting control through preferred stock. The company has appointed new leadership, including CEO Zameer Mulla, and plans...

Company Fundamentals
Bullish
3 hours ago
Star Bulk releases 2025 ESG report highlighting sustainability progress and future goals

Star Bulk releases 2025 ESG report highlighting sustainability progress and future goals

Star Bulk Carriers Corp. has published its 2025 Environmental, Social and Governance (ESG) Report, its eighth annual report detailing the company's sustainability strategy, performance, and future objectives. The report, guided by the ESG Committee, ...

Others
Bullish
3 hours ago
TELA Bio cuts operating loss 21% in Q3 2026, boosts international sales and extends cash runway to 2028

TELA Bio cuts operating loss 21% in Q3 2026, boosts international sales and extends cash runway to 2028

TELA Bio reported $19 million revenue in Q3 2026, down 8% year-over-year but with an 18% increase in international sales. The company reduced its operating loss by 21% sequentially and improved adjusted EBITDA loss by 55%, driven by a strategic cost ...

Company Fundamentals
Bullish
3 hours ago
Auburn National Bancorporation declares $0.27 quarterly dividend payable December 28, 2026.

Auburn National Bancorporation declares $0.27 quarterly dividend payable December 28, 2026.

Auburn National Bancorporation, Inc. announced a quarterly cash dividend of $0.27 per share, payable on December 28, 2026, to shareholders recorded by December 10, 2026. The company is the parent of AuburnBank, an Alabama state-chartered bank with ab...

Company Fundamentals
Neutral
5 hours ago
Québécois plan to dine out more in 2027, seeking value and local favorites, says OpenTable report.

Québécois plan to dine out more in 2027, seeking value and local favorites, says OpenTable report.

OpenTable's 2027 Quebec dining trends report shows a 9% increase in restaurant bookings, with 65% of Quebecers planning to dine out as much or more in 2027. Consumers prioritize value, local favorites, and meaningful experiences, often celebrating sm...

Market News
Bullish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App